Ohashi T, Kikuchi N and Yamamoto T: Unusual milia amyloidosis as initial signs of multiple myeloma-associated systemic amyloidosis. Int J Dermatol 52: 981-982, 2013.Unusual milia amyloidosis as initial signs of multiple myeloma‐associated systemic amyloidosis[J] . Takenobu Ohashi,Nobuyuki Kikuchi,...
In myeloma, the abnormal plasma cells eventually invade and destroy the outer hard layer of bone. The destruction of bones (osteolysis), typically occurring in small areas at different sites, may lead to serious problems. Even a small osteolytic lesioncan cause the bone to break -- or more ...
Ong F, Hermans J, Noordijk EM, Wijermans PW, Kluin-Nelemans JC. Presenting signs and symptoms in multiple myeloma: high percentages of stage III among patients without apparent myeloma-associated symptoms. Ann. Hematol. 1995 Mar;70(3):149- 52....
The risk of internal malignancies increases with age with approximately 60% of malignancies occurring in patients greater than 65 years of age. Id
Common complaints, difficult diagnosis: Multiple myeloma Purpose: To review the presenting signs and symptoms of multiple myeloma, its pathophysiology, diagnostic evaluation, and treatment options.Data sources: A... C Dvorak - 《Journal of the American Association of Nurse Practitioners》 被引量: 22...
Multiple Myelomas Multiple myeloma is a type of blood cancer that is derived from plasma cells, which are a type of immune cell. Brain and Spinal Cord Tumors: These tumors form in the nervous system of the body. Neuroendocrine Tumors They develop in cells that release hormones into your bl...
Cancer, as usual, saw the most approvals in 2023 with 16, including four bispecifics in a span of as many months. Two bispecifics for multiple myeloma—Talveyfrom Johnson & Johnson andElrexfiofrom Pfizer—made the grade. There also were two bispecifics approved for B-cell l...
What to Know About First Case of Severe Bird Flu From Prevention for AbbVie: Botox CM Advice for Managing Chronic Migraines Belinda Carlisle Details Mental Rock ‘Bottom’ From Prevention for Johnson & Johnson When You Face Multiple Myeloma with a Partner ...
In the first part of a 2-article series, Matthew Matasar, MD, MS, discusses where loncastuximab fits into the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma and the data that led to the antibody drug conjugate’s approval.
Myeloma This blood cancer is characterized by excess plasma cells in bone marrow. Plasma cells are a type of B cell that produces antibodies, which are proteins that help fight infection. This type of cancer spreads in the bone marrow and damages bones. ...